BACKGROUND: Relatively little is known regarding HIV disease natural history and response to antiretroviral treatments among Asian people infected with HIV. The Therapeutics Research, Education, and AIDS Training in Asia (TREAT Asia) HIV Observational Database (TAHOD) is a recently established collaborative observational cohort study that aims to assess HIV disease natural history in treated and untreated patients in the Asia-Pacific region. METHODS: Observational data are collected on HIV-infected patients from 11 sites in the Asia-Pacific region. Data are centrally aggregated for analyses, with the first baseline and retrospective data transferred in September 2003. Retrospective data were analyzed to assess the response to highly active antiretroviral treatment (HAART) over a 6-month period in terms of changes in CD4 count and proportions of patients achieving an undetectable HIV viral load (<400 copies/mL). RESULTS: By the end of May 2004, 1887 patients had been recruited to the TAHOD. Seventy-two percent of patients were male, with median age 36 years. Seventy-eight percent of patients reported HIV infection through heterosexual contact. Forty-three percent of patients had a previous AIDS diagnosis, of whom 55% had tuberculosis. The mean 6-month CD4 count increase was 115 cells/muL (SD=127) after starting triple-combination therapy. Smaller CD4 count increases were associated with a higher CD4 count before starting treatment, prior treatment with monotherapy or double therapy, and treatment with a HAART regimen containing a nucleoside reverse transcriptase inhibitor (NRTI) and/or protease inhibitor (PI) but without a nonnucleoside reverse transcriptase inhibitor (NNRTI). Five hundred and ninety-eight patients started HAART and had a viral load assessment at 6 months, with 69% attaining an undetectable viral load. Older patients, patients not exposed to HIV through heterosexual contact, and patients treated with HAART containing NRTIs and NNRTIs but without PIs were found to be more likely to achieve an undetectable level. CONCLUSION: Analyses of retrospective data in the TAHOD suggest that the overall response to HAART in Asian populations is similar to that seen in Western countries.
BACKGROUND: Relatively little is known regarding HIV disease natural history and response to antiretroviral treatments among Asian people infected with HIV. The Therapeutics Research, Education, and AIDS Training in Asia (TREAT Asia) HIV Observational Database (TAHOD) is a recently established collaborative observational cohort study that aims to assess HIV disease natural history in treated and untreated patients in the Asia-Pacific region. METHODS: Observational data are collected on HIV-infected patients from 11 sites in the Asia-Pacific region. Data are centrally aggregated for analyses, with the first baseline and retrospective data transferred in September 2003. Retrospective data were analyzed to assess the response to highly active antiretroviral treatment (HAART) over a 6-month period in terms of changes in CD4 count and proportions of patients achieving an undetectable HIV viral load (<400 copies/mL). RESULTS: By the end of May 2004, 1887 patients had been recruited to the TAHOD. Seventy-two percent of patients were male, with median age 36 years. Seventy-eight percent of patients reported HIV infection through heterosexual contact. Forty-three percent of patients had a previous AIDS diagnosis, of whom 55% had tuberculosis. The mean 6-month CD4 count increase was 115 cells/muL (SD=127) after starting triple-combination therapy. Smaller CD4 count increases were associated with a higher CD4 count before starting treatment, prior treatment with monotherapy or double therapy, and treatment with a HAART regimen containing a nucleoside reverse transcriptase inhibitor (NRTI) and/or protease inhibitor (PI) but without a nonnucleoside reverse transcriptase inhibitor (NNRTI). Five hundred and ninety-eight patients started HAART and had a viral load assessment at 6 months, with 69% attaining an undetectable viral load. Older patients, patients not exposed to HIV through heterosexual contact, and patients treated with HAART containing NRTIs and NNRTIs but without PIs were found to be more likely to achieve an undetectable level. CONCLUSION: Analyses of retrospective data in the TAHOD suggest that the overall response to HAART in Asian populations is similar to that seen in Western countries.
Authors: Colette J Smith; Caroline A Sabin; Fiona C Lampe; Sabine Kinloch-de-Loes; Helen Gumley; Anne Carroll; Beth Prinz; Mike Youle; Margaret A Johnson; Andrew N Phillips Journal: AIDS Date: 2003-05-02 Impact factor: 4.177
Authors: Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: N Kumarasamy; Suniti Solomon; Timothy P Flanigan; R Hemalatha; S P Thyagarajan; Kenneth H Mayer Journal: Clin Infect Dis Date: 2002-12-09 Impact factor: 9.079
Authors: Federico Pulido; Jose R Arribas; Jose M Miró; María A Costa; Juan González; Rafael Rubio; Jose M Peña; Miguel Torralba; Montserrat Lonca; Alicia Lorenzo; Concepcion Cepeda; Juan J Vázquez; Jose M Gatell Journal: J Acquir Immune Defic Syndr Date: 2004-04-01 Impact factor: 3.731
Authors: Sanjay Pujari; Preeyaporn Srasuebkul; Somnuek Sungkanuparph; Poh Lian Lim; Nagalingeswaran Kumarasamy; John Chuah; Ritesh N Kumar; Yi-Ming A Chen; Shinichi Oka; Jun Yong Choi; Man-Po Lee; Praphan Phanuphak; Adeeba Kamarulzaman; Christopher Lee; Zhang Fujie; Rosanna Ditangco; Vonthanak Saphonn; Thira Sirisanthana; Tuti Parwati Merati; Jeff Smith; Matthew G Law Journal: J Antivir Antiretrovir Date: 2009-11-01
Authors: T C Do; D Boettiger; M Law; S Pujari; F Zhang; R Chaiwarith; S Kiertiburanakul; M P Lee; R Ditangco; W W Wong; K V Nguyen; T P Merati; T T Pham; A Kamarulzaman; S Oka; E Yunihastuti; N Kumarasamy; P Kantipong; J Y Choi; O T Ng; N Durier; K Ruxrungtham Journal: HIV Med Date: 2016-08 Impact factor: 3.180
Authors: Nicole L De La Mata; Penh S Ly; Oon T Ng; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Annette H Sohn; Matthew G Law; Nagalingeswaran Kumarasamy Journal: Int J STD AIDS Date: 2017-03-21 Impact factor: 1.359
Authors: Rainer Puhr; Nagalingeswaran Kumarasamy; Penh Sun Ly; Oon Tek Ng; Kinh Van Nguyen; Tuti Parwati Merati; Thuy Thanh Pham; Man Po Lee; Jun Yong Choi; Jeremy L Ross; Matthew G Law Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: H Byakwaga; K Petoumenos; J Ananworanich; F Zhang; M A Boyd; T Sirisanthana; P C K Li; C Lee; C V Mean; V Saphonn; S F S Omar; S Pujari; P Phanuphak; P L Lim; N Kumarasamy; Y M A Chen; T P Merati; S Sungkanuparph; R Ditangco; S Oka; G Tau; J Zhou; M G Law; S Emery Journal: J Int Assoc Provid AIDS Care Date: 2013-02-19
Authors: Wasana Prasitsuebsai; Asha C Bowen; Joselyn Pang; Cees Hesp; Azar Kariminia; Annette H Sohn Journal: AIDS Patient Care STDS Date: 2010-02 Impact factor: 5.078
Authors: Awachana Jiamsakul; Stephen J Kerr; Oon Tek Ng; Man Po Lee; Romanee Chaiwarith; Evy Yunihastuti; Kinh Van Nguyen; Thuy Thanh Pham; Sasisopin Kiertiburanakul; Rossana Ditangco; Vonthanak Saphonn; Benedict L H Sim; Tuti Parwati Merati; Wingwai Wong; Pacharee Kantipong; Fujie Zhang; Jun Yong Choi; Sanjay Pujari; Adeeba Kamarulzaman; Shinichi Oka; Mahiran Mustafa; Winai Ratanasuwan; Boondarika Petersen; Matthew Law; Nagalingeswaran Kumarasamy Journal: Trop Med Int Health Date: 2016-03-29 Impact factor: 2.622
Authors: J Zhou; P C K Li; N Kumarasamy; M Boyd; Y M A Chen; T Sirisanthana; S Sungkanuparph; S Oka; G Tau; P Phanuphak; V Saphonn; F J Zhang; S F S Omar; C K C Lee; R Ditangco; T P Merati; P L Lim; J Y Choi; M G Law; S Pujari Journal: HIV Med Date: 2009-07-06 Impact factor: 3.180